• Chu-Ming Huang, Yi-Fan Hong, Shi-Hui Xing, Ke Xu, Chu-Kai Xu, Wei-Jie Zhang, Hui Li, Pei-Feng Zhang, and Chu-Wei Cai.
• Department of Neurosurgery, Shantou Central Hospital, Shantou, Guangdong, China.
• World Neurosurg. 2019 Sep 1; 129: e429-e435.

ObjectiveTo evaluate the 30-day outcomes of using the Enterprise stent to treat patients with hypoperfusion of symptomatic severe intracranial stenosis.MethodsPatients with symptomatic severe intracranial stenosis (70%-99%) who underwent Enterprise stent intervention between August 2014 and November 2018 were retrospectively analyzed. The 30-day primary outcomes included the success rate of stenting and the incidence of complications, including ischemic stroke, cerebral hemorrhage, and death. The 30-day complication rates of patients with different lesion locations and classifications of Mori morphology were compared.ResultsSixty-eight patients were treated using 70 Enterprise stents. The success rate was 100%. The 30-day complication rate was 4.4%. The rates of ischemic stroke, cerebral hemorrhage, and death were 1.5%, 2.9%, and 0%, respectively. No significant difference was found in the 30-day complication rate between patients with different lesion locations and classifications of Mori morphology (P > 0.05).ConclusionEnterprise stents were relatively safe in treating patients with hypoperfusion of symptomatic severe intracranial stenosis.Copyright © 2019 Elsevier Inc. All rights reserved.

5 keywords...

hide…